Abstract: Nine new 3′-N-phenylsulfonyl docetaxel analogs were synthesized in good yields from the key intermediate N-phenylsulfonyl oxazolidine via a six-step route. These analogs were tested for anti-hepatitis B virus (HBV) activity in vitro. Compounds 3e, 3g and 3j showed more potent inhibitory activity against HBeAg secretion than the positive control lamivudine. Further extensive SAR and mechanistic studies will be reported in due course.
Introduction
Hepatitis B virus (HBV) is a major cause of acute and chronic hepatitis which can lead to liver cirrhosis, liver failure and hepatocellular carcinoma [1] . It was estimated there are 350 million chronic carriers and that about 2 billion people have been infected, and an estimated 600,000 to 1.2 million people die each year from HBV-associated illnesses [2, 3] . Currently, therapies for HBV infection on market include immuno-modulators, interferons (interferon-alpha and pegylated interferon) and nucleoside analogues. However, these drugs still have their drawbacks. For example, immune-modulators (IFN-a and pegIFN-a) and polymerase inhibitors (lamivudine, entecavir, telbivudine and adefovir) are associated with a low cure rate, viral resistance, poor tolerability, and inefficiency in eradicating HBV [4] [5] [6] [7] . Therefore, there is a need to search for new anti-HBV agents with novel antiviral targets and mechanisms of action.
OPEN ACCESS
Natural products and their derivatives have always played a pivotal role as leads in drug discovery. Paclitaxel (1, Figure 1 ) and its semi-synthetic derivative docetaxel (Taxotere, 2), are currently considered to be the most important and promising anticancer agents in the treatment of refractory breast and ovarian cancers due to their unique mechanism of action by binding tubulin and stabilizing microtubule formation, which ultimately disrupts mitosis and causes cell death [8] . In our studies of docetaxel derivatives as anticancer agents [9, 10] , many analogs were synthesized, including one 3′-N-phenylsulfonyl docetaxel analog. It was found that this 3′-N-phenylsulfonyl docetaxel analog didn't show any potent antitumor activity [11, 12] . However, it has been reported that a large number of structurally novel sulfonamide derivatives have shown substantial antiviral activity both in vitro and in vivo [13, 14] . Accordingly, a series of novel 3′-N-phenylsulfonyl docetaxel analogs were designed, synthesized and investigated for their HBV inhibitory activity. It was hoped that a promising lead could be emerged from this type of structure. 
Results and Discussion

Chemistry
In order to synthesize these 3′-N-phenylsulfonyl docetaxel analogues, several synthetic routes were approached. The first attempt was to couple the intermediate N-de-tert-butoxy-carbonyl-7,10-ditrocdocetaxel (4) with phenylsulfonyl chloride directly (Scheme 1). , indicating a molecular weight of 829, or 18 Da lower than that of 5. Since the H-3′ peak had disappeared in 1 H-NMR spectrum, it was suggested that the dehydrated product 5′ was obtained rather than 5. Obviously the elimation occurred quickly since the benzenesulfonate is a very good leaving group formed by phenylsulfonyl and hydroxyl groups.
The second attempt was to synthesize the side chain from (2R,3S)-3-amino-2-hydroxy-3-phenylpropionic acid methyl ester (6) , as illustrated in Scheme 2. Compound 6 was transformed into phenylsulfonamide 7 with phenylsulfonyl chloride, followed by saponification to afford acid 8. However, the coupling reaction between 8 and the intermediate 7,10-ditroc-10-deacetylbaccatin failed to yield 5, partially because 8 was more prone to undergo self-condensation due to the steric hindrance of the hydroxyl group in 10-DAB. Since the free hydroxyl group in 7 interfered with the reaction, we decided to protect it first. Thus, after protecting the hydroxyl group of 7 with 2,2,2-trichloroethyl chloroformate (TrocCl) followed by saponification, the carboxylic acid 10 was obtained as expected. However, the desired product 5′′ was still not formed when 10 reacted with 7,10-ditroc-10-DAB.
Scheme 2.
Another attempted synthesis of compound 5. 
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Ke et al. reported the synthesis of novel 3′-N-tert-butylsulfonyl analogs of docetaxel by asymmetric synthesis of the side chain oxazolidine and condensing this oxazolidine with 7,10-ditroc-10-DAB [12] . Unfortunately, the oxazolidine is only obtained as diastereomeric mixtures via five steps from (R)-tert-butylsulfinylimine. We previously reported the synthesis of fluorinated docetaxel derivatives from the enantiopure N-Boc oxazolidine side chain [9, 10] . Therefore, N-phenylsulfonyl oxazolidine could be used as an important intermediate for this condensation reaction. Finally, compounds 3a-j were synthesized via a new six-step route in good yields from (2R,3S)-3-amino-2-hydroxy-3-phenyl-propionic acid methyl ester (6), a commercially available starting material, as illustrated in Scheme 3. Compound 6 was first transformed into phenylsulfonamides 7a-j with phenylsulfonyl chloride. Cyclic protection using methoxypropene in the presence of a catalytic amount of pyridinium para-toluenesulfonate (PPTS) followed by saponification of the formed intermediates 11a-j afforded acids 12a-j in 80%-95% yields. Then, key intermediates 12a-j were coupled with 7,10-ditroc-10-DAB in the presence of dicyclohexylcarbodiimide (DCC) and 4-dimethylaminopyridine (DMAP) to provide the corresponding intermediates 13a-j in 85%-95% yields. After removing the acetonide protecting group of 13a-j with 98% formic acid at room temperature, intermediates 5a-j were obtained in 57%-85% yields. After further deprotection of the 7,10-ditroc protecting groups on 5a-j with zinc in acetic acid, 3′-N-phenylsulfonyl docetaxel analogs 3a-j were synthesized in 53%-80% yields. 
Anti-HBV Activity
With compounds 3a-j in hand, they were tested for their antiviral activity against hepatitis B virus (HBV) in vitro [15] , and the results are summarized in Table 1 . Overall, the compounds showed only weak or no inhibitory activity on HBsAg secretion, except for compounds 3c and 3f, 3a-b, 3d-e and 3g-j that exhibited more potency against HBeAg secretion than the positive control lamivudine (12.5% at 873.4 μM). Especially, 3e, 3g and 3j showed inhibitory activity on HBeAg secretion by 44.4%, 47.0% and 40.2% at the maximum non-toxic concentration (12.5 μg/mL), respectively.
Preliminary structure-activity relationships (SAR) did not show a clear trend in terms of electron-withdrawing or electron-donating substituents on the phenyl ring. Only phenyl (3a), 4-methoxyl (3d), 4-chloro (3h) and benzyl (3b) analogs exihibited weaker inhibitory activity against both HBsAg secretion and HBeAg secretion. However, 4-isopropyl (3e), 4-trifluoromethyl (3g) and 2,4,6-trimethyl (3j) analogs demonstrated the most potent inhibitory activity against HBeAg secretion. Meanwhile, they were all inactive against HBsAg secretion. Accordingly, further extensive SAR study on the substituent pattern on phenyl ring and modification of the linker (based on the result of 3b) will be continued in the near future.
Experimental
General
Reagents were purchased from the Aldrich (Shanghai, China) and TCI Chemical (Shanghai, China) companies. All solvents are purified and dried in accordance with standard procedures, unless otherwise indicated. Reactions were monitored by TLC using Yantai (Yantai, China) GF254 silica gel plates (5 × 10 cm). Silica gel column chromatography was performed on silica gel (300-400 mesh) from Yantai. Melting points (mp) were determined using an X-4 microscope melting point apparatus and were uncorrected. All NMR spectra were recorded on a Bruker DRX-400 (400/100 MHz) spectrometer. Low-resolution mass spectra (ESI) were performed on a Shimadzu LCMS-2010EV and high-resolution mass spectra on a Bruker Daltonics, Inc. APEXIII7.0 TESLA FMS (ESI) . Elemental analysis was carried out on an Elementar Vario EL instrument.
Synthesis
General Procedure for the Synthesis of 7a-j
To a round-bottomed flask (2R,3S)-3-amino-2-hydroxy-3-phenyl-propionic acid methyl ester (6, 0.39 g, 2 mmol) was added into THF (15 mL), which was cooled to 0 o C. To this suspension was added Et 3 N (1.11 mL, 8 mmol), followed by the dropwise addition of phenylsulfonyl chloride (2.2 mmol). After further stirred at this temperature for 1 h, it was diluted with DCM (30 mL). The organic layer was washed with brine, dried over anhydrous Na 2 SO 4 and filtered. Then the filtrate was evaporated and the residue was purified by column chromatography using petroleum ether/EtOAc (2/1) to afford the products 7a-j as white solids. 
2-Hydroxy-3-benzenesulfonylamino-3-phenyl-propionic acid methyl ester (7a
General Procedure for the Synthesis of 11a-j
To a stirred solution of 7a-j (0.45 mmol) and PPTs (113 mg, 0.045 mmol) in anhydrous toluene (8 mL) was added 2-methoxypropene (0.129 mL, 1.35 mmol). The reaction mixture was warmed to 85 °C , and further stirred for 2 h at this temperature. After cooled down to room temperature, the mixture was diluted with EtOAc (50 mL). The organic layer was washed with brine, dried over anhydrous Na 2 SO 4 and filtered. The filtrate was evaporated and the residue was purified by silica gel column chromatography using petroleum ether/EtOAc (2/1) to obtain products 11a-j as colorless liquids. 
2,2-Dimethyl-3-benzenesulfonyl-4-phenyl-oxazolidine-5-carboxylic acid methyl ester (11a
2,2-Dimethyl-3-(4-methyl)benzenesulfonyl-4-phenyl-oxazolidine-5-carboxylic acid methyl ester (11c
2,2-Dimethyl-3-(4-methoxy)benzenesulfonyl-4-phenyl-oxazolidine-5-carboxylic acid methyl ester (11d).
Yield 99% (180 mg); 
2,2-Dimethyl-3-(4-isopropyl)benzenesulfonyl-4-phenyl-oxazolidine-5-carboxylic acid methyl ester (11e)
.
2,2-Dimethyl-3-(4-fluoro)benzenesulfonyl-4-phenyl-oxazolidine-5-carboxylic acid methyl ester (11f
2,2-Dimethyl-3-(4-trifluoromethyl)benzenesulfonyl-4-phenyl-oxazolidine-5-carboxylic acid methyl ester (11g
2,2-Dimethyl-3-(4-chloro)benzenesulfonyl-4-phenyl-oxazolidine-5-carboxylic acid methyl ester (11h
2,2-Dimethyl-3-(4-bromo)benzenesulfonyl-4-phenyl-oxazolidine-5-carboxylic acid methyl ester (11i
General Procedure for the Synthesis of 12a-j
To a stirred solution of 11a-j (0.437 mmol) in a mixture of solvent (THF:H 2 O = 6 mL:2 mL) at 0 °C was added LiOH•H 2 O (37 mg, 0.87 mmol). The resulting mixture was warmed to room temperature and further stirred for 1 h. Then the pH of the mixture was adjusted to 2~3 by adding 1N HCl solution. After extracted with CH 2 Cl 2 three times, the combined organic phase was dried over anhydrous Na 2 SO 4 and evaporated to afford the colorless liquid products 12a-j. 
2,2-Dimethyl-3-benzenesulfonyl-4-phenyl-oxazolidine-5-carboxylic acid (12a
2,2-Dimethyl-3-(4-methyl)benzenesulfonyl-4-phenyl-oxazolidine-5-carboxylic acid (12c
2,2-Dimethyl-3-(4-methoxy)benzenesulfonyl-4-phenyl-oxazolidine-5-carboxylic acid (12d
2,2-Dimethyl-3-(4-isopropyl)benzenesulfonyl-4-phenyl-oxazolidine-5-carboxylic acid (12e
General Procedure for the Synthesis of 13a-j
To a solution of anhydrous toluene (60 mL) were added 12a-j (0.49 mmol), 7,10-ditroc-10-DAB (0.23 g, 0.24 mmol), DCC (0.15 g, 0.75 mmol) and DMAP (15 mg, 0.13 mmol). The resulting mixture was stirred at 85 °C for 3 h. After the completion, the reaction mixture was washed with brine (30 mL × 3), dried over Na 2 SO 4 , filtered and concentrated in vacuo. The obtained residue was purified by silica gel flash chromatography column (petroleum ether/ethyl acetate: 4/1) to afford 13a-j as white solids. C-NMR (CDCl 3 ) δ 200.65, 170.12, 169.73, 166.85, 153.21, 142.39, 139.64, 136.63, 133.90, 132.06, 131.66 
7,10-Di(2,2,2-trichloroethyloxycarbonyl)-10-deacetylbaccatin III-13-O-[2,2-dimethyl-3-(4-methyl) benzene sulfonyl-4-phenyl-oxazolidine-5-carboxylate] (13c
7,10-Di(2,2,2-trichloroethyloxycarbonyl)-10-deacetylbaccatin III-13-O-[2,2-dimethyl-3-(4-methoxy) benzene sulfonyl-4-phenyl-oxazolidine-5-carboxylate] (13d
7,10-Di(2,2,2-trichloroethyloxycarbonyl)-10-deacetylbaccatin III-13-O-[2,2-dimethyl-3-(4-isopropyl) benzene sulfonyl-4-phenyl-oxazolidine-5-carboxylate] (13e
7,10-Di(2,2,2-trichloroethyloxycarbonyl)-10-deacetylbaccatin III-13-O-[2,2-dimethyl-3-(4-fluoro) benzene sulfonyl-4-phenyl-oxazolidine-5-carboxylate] (13f
7,10-Di(2,2,2-trichloroethyloxycarbonyl)-10-deacetylbaccatin III-13-O-[2,2-dimethyl-3-(4-bromo) benzene sulfonyl-4-phenyl-oxazolidine-5-carboxylate] (13i
7,10-Di(2,2,2-trichloroethyloxycarbonyl)-10-deacetylbaccatin III-13-O-[2,2-dimethyl-3-(2,4,6-trimethyl) benzene sulfonyl-4-phenyl-oxazolidine-5-carboxylate] (13j
General Procedure for the Synthesis of 5a-j
To a round-bottomed flask (25 mL) were added 13a-j (0.218 mmol) and HCOOH (>98%, 5 mL). The reaction mixture was stirred at room temperature for 4 h. Then the resulting solution was neutralized by addition of saturated NaHCO 3 . After extracted with EtOAc three times, the combined organic phase was washed with brine, dried over Na 2 SO 4 , filtered, and concentrated in vacuo. The obtained residue was purified by silica gel flash chromatography column (acetone/petroleum ether: 1/3) to afford 5a-j as white solids.
N-De-tert-butoxycarbonyl-N-phenylsulfonyl 7,10-di(2,2,2-trichloroethyloxycarbonyl)-docetaxel (5a).
Yield 72% (188 mg); mp 156-158 °C; C-NMR (CDCl 3 ) δ 200.62, 170.61, 166.78, 153.22, 142.02, 140.18, 136.31, 133.88, 132.62,  132.30, 130.13, 129.04, 128.81, 128.72, 128.65, 128.36, 127.05, 126.91, 94.17, 83.60, 80.95, 79.12,  78.61, 74.62, 74.12, 72.10, 60.42, 59.50, 56.27, 46.92, 43.02, 35.53, 33.28, 26.50, 22.46, 20.73, 14.91 
N-De-tert-butoxycarbonyl-N-(4-methyl)-phenylsulfonyl 7,10-di(2,2,2-trichloroethyloxycarbonyl)-docetaxel (5c)
General Procedure for the Synthesis of 3a-j
To a solution of 5a-j (0.19 mmol) in methanol (10 mL) were added glacial acetic acid (4.60 mL) and zinc powder (0.46 g, 7.08 mmol). After stirred at 50 °C for 1 h, the reaction mixture was filtered to remove the zinc and solid formed. The filtrate was evaporated by distillation to give a white solid. The obtained solid was then dissolved in ethyl acetate (60 mL), which was washed with saturated NaHCO 3 , brine, dried over Na 2 SO 4 , and concentrated in vacuo. The obtained residue was further purified by silica gel flash chromatography column (petroleum ether/acetone: 2/1) to give 3a-j. 
N-De-tert-butoxycarbonyl-N-phenylsulfonyl docetaxel (3a
